This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring
March 18–20, 2024 | Barcelona, SpainMarch 26–27, 2024 | Digital Partnering

Stephane Thiroloix
CEO at AlgoTx


Stéphane Thiroloix founded AlgoTx in April 2018 with co-Founder Olivier Bohuon. He is AlgoTx CEO and Chairman of the Board. AlgoTx develops novel therapies for complex pain. AlgoTx was awarded the 2023 ESG HealthTech Trophy in recognition of the biotech’s early commitment to ESG initiatives.

Stephane graduated in 1986 from the HEC business school. He is an investor in a dozen startup companies, a Board Member at Jellagen Ltd and Hoalen, a lecturer at Essec Business School and a member of the Evaluation Committee of the Paris Biotech Santé incubator.

Stéphane spent eleven years at Roussel Uclaf (now Sanofi), in various Mkg & Sales and General Management positions in South Africa, Mexico, Australia and France.

In 1998 he joined SmithKline Beecham (now GSK) as VP Operations in France, then European VP Business Development and Marketing Alliances.

From 2002 to 2007, Stephane was VP French Operations for Bristol-Myers Squibb in France and then European VP and GM France.

In 2007, he joined the Executive Committee of Ipsen, a France-based global biopharmaceutical company, as Executive VP Corporate Development, with responsibility for Business Development and Legal Affairs, Pre-clinical and Clinical Development, Regulatory Affairs.

From 2011 to 2014, Stéphane Thiroloix was President Europe, Canada, Japan and Australia for the Advanced Surgical Devices division of the global medical devices company Smith & Nephew.

From 2014 to 2018, Stéphane was CEO of Mayoly Spindler, an independent European pharmaceutical company focused on gastro-enterology and dermo-cosmetics.

Agenda Sessions

  • For a greener globe: biopharma's journey towards a sustainable future